Philip J. Campbell

Geelong, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Journal: The Lancet. Oncology
Published: May 06, 2024

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Journal: Blood advances
Published: December 29, 2023

A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia.

A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia.

Journal: Internal medicine journal
Published: February 12, 2023

Telehealth in cancer care during the COVID-19 pandemic.

Telehealth in cancer care during the COVID-19 pandemic.

Journal: Journal of telemedicine and telecare
Published: December 09, 2022

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study.

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study.

Journal: Research and practice in thrombosis and haemostasis
Published: December 04, 2022

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population.

Journal: British journal of haematology
Published: November 02, 2022

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.

Journal: HemaSphere
Published: July 07, 2022

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Journal: Leukemia & lymphoma
Published: July 15, 2021

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Journal: BMC cancer
Published: September 29, 2020

Indium-labelled autologous platelet sequestration studies predict response to splenectomy in immune thrombocytopenia: an Australian experience.

Indium-labelled autologous platelet sequestration studies predict response to splenectomy in immune thrombocytopenia: an Australian experience.

Journal: Internal medicine journal
Published: September 15, 2020

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.

Journal: Internal medicine journal
Published: April 03, 2020
Showing 1-12 of 26

Last Updated: 09/26/2026